- Date: March 08, 2018
The Barcelona company ABAC Therapeutics has closed a Series A financing round worth 16 million euros. Specialised in discovering new antibiotics to combat multidrug-resistant bacteria, ABAC plans to allocate these funds to bring its anti-Acinetobacter baumanii programme to the clinical trial phase.
The aforementioned bacterium is a frequent cause of hospital infections, and it tops the list drawn up by the World Health Organisation of pathogens that urgently require new treatments.
Caixa Capital Risc was one of the participants in this round of financing, together with the Pontifax fund, the Global Health Science Fund, the Debiopharm Innovation Fund and the pharmaceutical company Ferrer.
December 18, 2018
The EIT Health Summit, held on 4-5 December in Łódź (Poland), brought together over 400 experts in medical innovation from all over Europe.
November 29, 2018
”La Caixa” Banking Foundation (LCF) has launched the second edition of the open call for Health Research projects, which will remain open until 15 January.
November 27, 2018
Highly innovative start-ups and SMEs from Spain and Portugal are invited to apply for the EntrepreneurXXI Awards until 12 December.